University of Maryland’s Owonikoko: What it means to be a Black director of an NCI-designated cancer center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A month after reporting to work in the top job at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Taofeek K. Owonikoko reflected on the obligations that come with being a Black director of an NCI-designated cancer center:

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Amy Lacey
VCU Massey Comprehensive Cancer Center
Otis W. Brawley, MD, MACP
Bloomberg Distinguished Professor of Oncology and Epidemiology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Former chief medical and scientific officer, American Cancer Society
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
Amy Lacey
VCU Massey Comprehensive Cancer Center
Otis W. Brawley, MD, MACP
Bloomberg Distinguished Professor of Oncology and Epidemiology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; Former chief medical and scientific officer, American Cancer Society
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login